Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder caused by a complex
hypersensitivity response to antigens released by the fungus Aspergillus fumigatus. Oral
corticosteroids are currently the treatment of choice for ABPA associated with bronchial
asthma. They not only suppress the immune hyperfunction but are also anti-inflammatory.
However, there is no data to guide the dose and duration of glucocorticoids and different
regimens of glucocorticoids have been used in literature. The disorder is highly prevalent in
India. The investigators have previously reported their experience with screening stable
outpatients with bronchial asthma and acute severe asthma for ABPA. The investigators have
also recently reported the prognostic factors associated with clinical outcomes in patients
with ABPA.
The aim of this prospective randomized controlled trial (RCT) is to evaluate the efficacy and
safety of two different glucocorticoid dose protocols in patients with ABPA.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research